New combo therapy shows promise for older hodgkin lymphoma patients
NCT ID NCT01476410
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see how many patients achieved complete remission. The approach aims to improve outcomes by targeting cancer cells more precisely while using chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD chemotherapy)
- What this could lead to
- If successful, this combination could offer a more effective treatment option for older adults with Hodgkin lymphoma, potentially leading to higher remission rates.
- What could go wrong
- This is a small phase II trial with only 49 participants, so results may not apply to all patients. Side effects from chemotherapy and the targeted drug can be serious, and long-term outcomes are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan- Kettering Cancer Center
New York, New York, 10065, United States
-
NorthwesternU
Chicago, Illinois, 60611, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7835, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial